519 related articles for article (PubMed ID: 27671673)
1. Extended use up to 5 years of the etonogestrel-releasing subdermal contraceptive implant: comparison to levonorgestrel-releasing subdermal implant.
Ali M; Akin A; Bahamondes L; Brache V; Habib N; Landoulsi S; Hubacher D;
Hum Reprod; 2016 Nov; 31(11):2491-2498. PubMed ID: 27671673
[TBL] [Abstract][Full Text] [Related]
2. A 3-year multicentre randomized controlled trial of etonogestrel- and levonorgestrel-releasing contraceptive implants, with non-randomized matched copper-intrauterine device controls.
Bahamondes L; Brache V; Meirik O; Ali M; Habib N; Landoulsi S;
Hum Reprod; 2015 Nov; 30(11):2527-38. PubMed ID: 26409014
[TBL] [Abstract][Full Text] [Related]
3. A randomized clinical trial of the effect of intensive versus non-intensive counselling on discontinuation rates due to bleeding disturbances of three long-acting reversible contraceptives.
Modesto W; Bahamondes MV; Bahamondes L
Hum Reprod; 2014 Jul; 29(7):1393-9. PubMed ID: 24812309
[TBL] [Abstract][Full Text] [Related]
4. Immediate versus delayed insertion of an etonogestrel releasing implant at medical abortion-a randomized controlled equivalence trial.
Hognert H; Kopp Kallner H; Cameron S; Nyrelli C; Jawad I; Heller R; Aronsson A; Lindh I; Benson L; Gemzell-Danielsson K
Hum Reprod; 2016 Nov; 31(11):2484-2490. PubMed ID: 27664217
[TBL] [Abstract][Full Text] [Related]
5. A multicenter randomized clinical trial of etonogestrel and levonorgestrel contraceptive implants with nonrandomized copper intrauterine device controls: effect on weight variations up to 3 years after placement.
Bahamondes L; Brache V; Ali M; Habib N;
Contraception; 2018 Sep; 98(3):181-187. PubMed ID: 29777663
[TBL] [Abstract][Full Text] [Related]
6. A 12-month multicenter, randomized study comparing the levonorgestrel intrauterine system with the etonogestrel subdermal implant.
Apter D; Briggs P; Tuppurainen M; Grunert J; Lukkari-Lax E; Rybowski S; Gemzell-Danielsson K
Fertil Steril; 2016 Jul; 106(1):151-157.e5. PubMed ID: 27016644
[TBL] [Abstract][Full Text] [Related]
7. A prospective, open-label, single arm, multicentre study to evaluate efficacy, safety and acceptability of pericoital oral contraception using levonorgestrel 1.5 mg.
Festin MP; Bahamondes L; Nguyen TM; Habib N; Thamkhantho M; Singh K; Gosavi A; Bartfai G; Bito T; Bahamondes MV; Kapp N
Hum Reprod; 2016 Mar; 31(3):530-40. PubMed ID: 26830816
[TBL] [Abstract][Full Text] [Related]
8. Estimated disability-adjusted life years averted by long-term provision of long acting contraceptive methods in a Brazilian clinic.
Bahamondes L; Bottura BF; Bahamondes MV; Gonçalves MP; Correia VM; Espejo-Arce X; Sousa MH; Monteiro I; Fernandes A
Hum Reprod; 2014 Oct; 29(10):2163-70. PubMed ID: 25085802
[TBL] [Abstract][Full Text] [Related]
9. Acceptability of the levonorgestrel releasing-intrauterine system and etonogestrel implant: one-year results of an observational study.
Short M; Dallay D; Omokanye S; Hanisch JU; Inki P
Eur J Contracept Reprod Health Care; 2012 Feb; 17(1):79-88. PubMed ID: 22200172
[TBL] [Abstract][Full Text] [Related]
10. Prolonged use of the etonogestrel implant and levonorgestrel intrauterine device: 2 years beyond Food and Drug Administration-approved duration.
McNicholas C; Swor E; Wan L; Peipert JF
Am J Obstet Gynecol; 2017 Jun; 216(6):586.e1-586.e6. PubMed ID: 28147241
[TBL] [Abstract][Full Text] [Related]
11. Changes in body composition in women using long-acting reversible contraception.
Silva Dos Santos PN; Madden T; Omvig K; Peipert JF
Contraception; 2017 Apr; 95(4):382-389. PubMed ID: 28041992
[TBL] [Abstract][Full Text] [Related]
12. Acceptability of long-acting, progestin-only contraception in Europe: a two-year prospective, non-interventional study.
Short M; Dallay D; Omokanye S; Stauch K; Inki P
Eur J Contracept Reprod Health Care; 2014 Feb; 19(1):29-38. PubMed ID: 24289528
[TBL] [Abstract][Full Text] [Related]
13. Menstrual characteristics and ultrasonographic uterine cavity measurements predict bleeding and pain in nulligravid women using intrauterine contraception.
Kaislasuo J; Heikinheimo O; Lähteenmäki P; Suhonen S
Hum Reprod; 2015 Jul; 30(7):1580-8. PubMed ID: 25990577
[TBL] [Abstract][Full Text] [Related]
14. Rates and outcomes of planned pregnancy after use of Norplant capsules, Norplant II rods, or levonorgestrel-releasing or copper TCu 380Ag intrauterine contraceptive devices.
Sivin I; Stern J; Diaz S; Pavéz M; Alvarez F; Brache V; Mishell DR; Lacarra M; McCarthy T; Holma P
Am J Obstet Gynecol; 1992 Apr; 166(4):1208-13. PubMed ID: 1566771
[TBL] [Abstract][Full Text] [Related]
15. Endometriosis-associated pain scores and biomarkers in users of the etonogestrel-releasing subdermal implant or the 52-mg levonorgestrel-releasing intrauterine system for up to 24 months.
Margatho D; Carvalho NM; Bahamondes L
Eur J Contracept Reprod Health Care; 2020 Apr; 25(2):133-140. PubMed ID: 32069126
[No Abstract] [Full Text] [Related]
16. HIV incidence among women using intramuscular depot medroxyprogesterone acetate, a copper intrauterine device, or a levonorgestrel implant for contraception: a randomised, multicentre, open-label trial.
Evidence for Contraceptive Options and HIV Outcomes (ECHO) Trial Consortium
Lancet; 2019 Jul; 394(10195):303-313. PubMed ID: 31204114
[TBL] [Abstract][Full Text] [Related]
17. Weight change at 12 months in users of three progestin-only contraceptive methods.
Vickery Z; Madden T; Zhao Q; Secura GM; Allsworth JE; Peipert JF
Contraception; 2013 Oct; 88(4):503-8. PubMed ID: 23582238
[TBL] [Abstract][Full Text] [Related]
18. Control of endometriosis-associated pain with etonogestrel-releasing contraceptive implant and 52-mg levonorgestrel-releasing intrauterine system: randomized clinical trial.
Carvalho N; Margatho D; Cursino K; Benetti-Pinto CL; Bahamondes L
Fertil Steril; 2018 Nov; 110(6):1129-1136. PubMed ID: 30396557
[TBL] [Abstract][Full Text] [Related]
19. Subdermal contraceptive implants.
Peralta O; Diaz S; Croxatto H
J Steroid Biochem Mol Biol; 1995 Jun; 53(1-6):223-6. PubMed ID: 7626459
[TBL] [Abstract][Full Text] [Related]
20. Removal of a well-palpable one-rod subdermal contraceptive implant using a dedicated hand-held device or standard technique: a randomized, open-label, non-inferiority trial.
Hubacher D; Byamugisha J; Kakaire O; Nalubwama H; Emtell Iwarsson K; Bratlie M; Chen PL; Gemzell-Danielsson K
Hum Reprod; 2022 Sep; 37(10):2320-2333. PubMed ID: 35960174
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
